Gradient Investments’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Gradient Investments’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-65	Closed	–	–	1703
2022 Q3	$0	Hold	65	–	–	﹤0.01%	1605
2022 Q2	$0	Buy	+65	New	+$33	﹤0.01%	1438

Gradient Investments's LOGC Position: Q4 2022 in Review

Gradient Investments sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 65 shares.

Gradient Investments first reported a position in LOGC in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Gradient Investments reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Gradient Investments sold 65 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
Gradient Investments first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Gradient Investments's LogicBio Therapeutics, Inc. Common Stock position peaked at $0 in Q3 2022.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Gradient Investments's 13F filing for Q4 2022, filed 10 Jan 2023.